By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Progenics Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-789-2800 Fax: 914-789-2817


Progenics Pharmaceuticals, Inc., of Tarrytown, NY is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward symptom management and supportive care and the treatment of HIV infection and cancer. The Company has four product candidates in clinical development and several others in preclinical development.

The Company, in collaboration with Wyeth, is developing methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative bowel dysfunction. In the area of HIV infection, the Company is developing the viral-entry inhibitor PRO 140, a humanized monoclonal antibody targeting the HIV coreceptor CCR5 (in phase 1b studies). In addition, the Company is conducting research on ProVax, a novel prophylactic HIV vaccine. The Company is developing in vivo immuno-therapies for prostate cancer, including a human monoclonal antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells. Progenics is also developing vaccines designed to stimulate an immune response to PSMA. A recombinant PSMA vaccine is in phase 1 clinical testing. The Company is also developing a cancer vaccine, GMK, in phase 3 clinical trials for the treatment of malignant melanoma.

Last Updated: 06-09-2006

Key Statistics

Ownership: Public

Web Site: Progenics
Symbol: PGNX

Company News
FDA Extends Action Date for Progenics (PGNX), Valeant (VRX)'s NDA for Oral RELISTOR 4/4/2016 5:52:37 AM
Progenics (PGNX) To Present At Upcoming Investor Conferences 2/1/2016 7:59:55 AM
Progenics (PGNX) Makes $7 Million Bid for EXINI Diagnostics 10/13/2015 6:27:08 AM
Phase II Dosimetry Data For Progenics Pharmaceuticals, Inc. (PGNX)’ AZEDRA Presented At EANM Congress 2015 10/12/2015 7:13:58 AM
Progenics Pharmaceuticals, Inc. (PGNX) To Host Research And Development Day On October 1, 2015 9/25/2015 7:55:06 AM
Valeant (VRX) And Progenics Pharmaceuticals, Inc. (PGNX) Announce FDA Acceptance Of NDA Submission For Oral RELISTOR 9/8/2015 6:18:34 AM
Progenics Pharmaceuticals, Inc. (PGNX) Announces Second Quarter 2015 Financial Results 8/6/2015 10:38:06 AM
Progenics Pharmaceuticals, Inc. (PGNX) Announces Exclusive Worldwide Licensing Agreement With Johns Hopkins University For Agent To Image Prostate Cancer Using PET Scan 8/4/2015 7:20:02 AM
Progenics Pharmaceuticals, Inc. (PGNX) Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma And Paraganglioma 7/28/2015 7:03:34 AM
Progenics Pharmaceuticals, Inc. (PGNX) Sets Second Quarter Financial Results Call For August 6 7/21/2015 7:28:00 AM